Aurinia Pharmaceuticals Inc

Price is in a Stage 1 consolidation following a parabolic collapse, oscillating sideways with compressed volatility and neutral momentum. The active Post-Parabola Collapse pattern implies persistent supply and supports a bearish medium-term bias, despite the underlying long-term uptrend. In the short term, price has rallied into flat-to-declining EMAs and been rejected, offering an immediate signal to sell into resistance. Execution is optimally placed at the 9/21 EMA zone, with rejection-based interaction.

• ↑Q4 2025 revenue of $77.1M, up 29% YoY
• ↑2026 net product sales expected $305M–$315M (+12%–16%)
• ↓Exclusivity ends January 2026; generic entrants threaten market share